# A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Source: https://onco.cc/trials/nct03424005/  
OnCo record `nct03424005` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Capecitabine, Atezolizumab, Ipatasertib, Bevacizumab, Carboplatin and Eribulin in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.

## Summary

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer is a phase 1/2 interventional study registered as NCT03424005 by Hoffmann-La Roche, with 1132 participants planned, started 2018-03-30 and due to reach its primary completion in 2030-09-30. Interventions recorded: Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab and Chemotherapy (Gemcitabine + Carboplatin or Eribulin).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03424005
- Phase: 1/2
- Setting: A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)
- Sponsor: Hoffmann-La Roche
- Enrolled: 1132

## Sources

- ClinicalTrials.gov NCT03424005: https://clinicaltrials.gov/study/NCT03424005

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Eribulin](https://onco.cc/drugs/eribulin/), [Ipatasertib](https://onco.cc/drugs/ipatasertib/), [Selicrelumab](https://onco.cc/drugs/selicrelumab/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/), [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct03424005.json